On February 6, 2023 Domain Therapeutics ("Domain" or "the Company"), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), reported that investor and industry conferences that its Chief Executive Officer, Pascal Neuville, will attend or speak at in the first half of 2023 (Press release, Domain Therapeutics, FEB 6, 2023, View Source [SID1234626867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OBIO Investor Summit, World Trade Centre, Toronto, Canada – 8-9 February

Presentation slot: February 9th, 3:30 p.m., Room C/D
LSX World Congress, London, UK – 3-4 May

Bio€quity, Dublin, Ireland – 14-16 May

Presentation slot: to be announced at a later date